ArticleScience advances2020
Targeted anti-IL-1β platelet microparticles for cardiac detoxing and repair.
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
59 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Engineered extracellular vesicles for ischemic heart diseases: modification methods, targeted delivery strategies, and multi-modal therapies - A systematic review.Frontiers in cardiovascular medicine · 2026Pooled it
- Avenues for optimization of cardiac therapeutics by minimally invasive delivery.Acta biomaterialia · 2026Review
- Single-Chain Anti-IL-1β Antibody Carried by Outer Membrane Vesicles of Bacteroides fragilis Alleviates Tubular Inflammation in Chronic Kidney Disease.Journal of extracellular vesicles · 2026Article
- Stromal-platelet membrane-inspired nanoparticles (SPIN) for targeted heart repair.Bioactive materials · 2025Article
- Extruded nanovesicles derived from umbilical cord mesenchymal stem cells exhibit No tumorigenic potential.Bioactive materials · 2025Article
- Pretreated exosomes by electrical stimulation accelerate bone regeneration.Bioactive materials · 2025Article
- A programmable platelet theranostic platform for adaptive multi-stage delivery and synergistic immunotherapy in atherosclerosis.Nature communications · 2025Article
- High-Resolution Patterned Delivery of Chemical Signals From 3D-Printed Picoliter Droplet Networks.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- MicroRNAs won the Nobel Prize. Now, can extracellular vesicles help them become drugs?Extracellular vesicle · 2025Article
- Lipidomic analysis of plant-derived extracellular vesicles for guidance of potential anti-cancer therapy.Bioactive materials · 2025Article
- Platelet Membrane and miR-181a-5p Doubly Optimized Nanovesicles Enhance Cardiac Repair Post-Myocardial Infarction through Macrophage Polarization.ACS applied materials & interfaces · 2025Article
- Injectable hydrogel with miR-222-engineered extracellular vesicles ameliorates myocardial ischemic reperfusion injury via mechanotransduction.Cell reports. Medicine · 2025Article
- Anti-inflammatory Therapies for Ischemic Heart Disease.Current cardiology reports · 2025Review
- Mechanisms of mitochondrial damage-associated molecular patterns associated with inflammatory response in cardiovascular diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- Natural, Engineered, and Hybrid Platelet Membrane-Based Nanotherapeutics for Inflammatory Diseases.International journal of nanomedicine · 2025Review
- Luteolin Nanomedicine with Stimulus-Driven Traceless Release for Targeting Treatment of Atherosclerosis by Enhancing Lipid Efflux.Research (Washington, D.C.) · 2025Article
- Trajectory of Cardiogenic Dementia: A New Perspective.Journal of cellular and molecular medicine · 2025Review
- Inflamed Skin, Burdened Heart: A Multidisciplinary Perspective on Atopic Dermatitis and Cardiovascular Health.Clinical, cosmetic and investigational dermatology · 2025Review
- Exploring COX-Independent Pathways: A Novel Approach for Meloxicam and Other NSAIDs in Cancer and Cardiovascular Disease Treatment.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Engineering supramolecular peptide nanofibers for in vivo platelet-hitchhiking beyond ligand-receptor recognition.Science advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
An acute myocardial infarction (AMI) induces a sterile inflammatory response that facilitates further heart injury and promotes adverse cardiac remodeling. Interleukin-1β (IL-1β) plays a central role in the sterile inflammatory response that results from AMI. Thus, IL-1β blockage is a promising strategy for treatment of AMI. However, conventional IL-1β blockers lack targeting specificity. This increases the risk of serious side effects. To address this problem herein, we fabricated platelet microparticles (PMs) armed with anti-IL-1β antibodies to neutralize IL-1β after AMI and to prevent adverse cardiac remodeling. Our results indicate that the infarct-targeting PMs could bind to the injured heart, increasing the number of anti-IL-1β antibodies therein. The anti-IL-1β platelet PMs (IL1-PMs) protect the cardiomyocytes from apoptosis by neutralizing IL-1β and decreasing IL-1β-driven caspase-3 activity. Our findings indicate that IL1-PM is a promising cardiac detoxification agent that removes cytotoxic IL-1β during AMI and induces therapeutic cardiac repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.